180 Life Sciences CORP Form 4 insider transactions
180 Life Sciences Corp. Director Stephen H. Shoemaker acquired 919,761 non-qualified stock options at an exercise price of $2.92, aligning his interests with shareholders.
A director at 180 Life Sciences Corp. was granted over 3.9 million stock options, contingent on future events and shareholder approval.
CEO Blair Jordan's latest SEC Form 4 filing details significant beneficial ownership changes and new stock option grants in 180 Life Sciences Corp.
180 Life Sciences Corp. announced the accelerated vesting of 110,000 non-qualified stock options for Director Lawrence Steinman, effective July 12, 2025, contingent upon stockholder approval of the 2025 Option Incentive Plan.
Stephen H. Shoemaker, a Director at 180 Life Sciences Corp., had 165,000 non-qualified stock options with an exercise price of $0.929 per share accelerate their vesting on July 12, 2025, subject to stockholder approval of the Company's 2025 Option Incentive Plan.
Form 4: 180 Life Sciences Director's Stock Options Vesting Accelerated, Contingent on Shareholder Approval
180 Life Sciences Corp. announced the accelerated vesting of 255,000 non-qualified stock options for Director Ryan Lewis Smith, subject to future stockholder approval of the company's 2025 Option Incentive Plan.
180 Life Sciences Corp. has accelerated the vesting of 25,000 non-qualified stock options for its Chief Accounting Officer, Eric R. Van Lent, subject to stockholder approval of the company's 2025 Option Incentive Plan.
Blair Jordan, CEO of 180 Life Sciences Corp., reported a transfer of 160,000 common shares to a controlled entity for tax planning, along with accelerated vesting of 410,000 stock options and significant beneficial ownership through voting agreements.
An amended SEC filing reveals that 180 Life Sciences Corp. retroactively adjusted a director's equity compensation, including restricted stock and stock options, to ensure compliance with the company's equity plan.
4/A: 180 Life Sciences Director Amends Equity Award Filing, Details Restricted Stock and Option Grants
180 Life Sciences Corp. Director Ryan Smith filed an amended Form 4 detailing the acquisition of 102,181 restricted common shares and 255,000 non-qualified stock options, with vesting tied to continued service and option exercise contingent on stockholder approval.
Stephen H. Shoemaker, a Director of 180 Life Sciences Corp., filed an amended Form 4 detailing the acquisition of 67,439 restricted common shares and 165,000 non-qualified stock options as compensation for board service.
4/A: 180 Life Sciences CEO Blair Jordan's Equity Award Adjusted, Significant Voting Control Disclosed
180 Life Sciences Corp. CEO Blair Jordan's equity compensation was retroactively adjusted, and the filing details his direct and indirect beneficial ownership, including significant voting control over shares held by other parties.
180 Life Sciences Corp. filed an amended Form 4 to reflect a retroactive adjustment to equity awards granted to Chief Accounting Officer Eric R. Van Lent, including restricted stock and stock options.
Stephen H. Shoemaker, a Director of 180 Life Sciences Corp., was granted 72,297 restricted common stock shares and 165,000 non-qualified stock options as compensation for his board service.
Lawrence Steinman, a Director at 180 Life Sciences Corp., was granted 48,198 shares of common stock and 110,000 non-qualified stock options as compensation for his services.
180 Life Sciences Corp. CEO Blair Jordan has significantly increased his beneficial ownership and voting control through new equity compensation and irrevocable voting proxies from key shareholders.
180 Life Sciences Corp. has granted 8,763 restricted common shares and 25,000 non-qualified stock options to Chief Accounting Officer Eric R. Van Lent as part of his compensation.
180 Life Sciences Corp. Director Ryan Lewis Smith has been granted 109,541 restricted common stock shares and 255,000 non-qualified stock options as compensation for his services.
Form 4: 180 Life Sciences CEO Blair Jordan Reports Changes in Beneficial Ownership Due to Voting Agreements
Blair Jordan, CEO of 180 Life Sciences Corp., reports changes in beneficial ownership due to voting agreements with multiple parties, granting him irrevocable voting proxies over their shares.
Elray Resources, Inc. converted its Series B Convertible Preferred Stock into 1,318,000 shares of common stock in 180 Life Sciences Corp.
CEO Jordan Blair gains voting control over 243,166 shares of 180 Life Sciences Corp. through voting agreements with shareholders.
Director Stephen Shoemaker acquired 65,000 shares of 180 Life Sciences Corp. common stock on February 20, 2025, as compensation for services.
Jay Lawrence Goodman, a director of 180 Life Sciences Corp., acquired 65,000 shares of common stock as compensation for services rendered.
Blair Jordan, CEO of 180 Life Sciences Corp., reports acquiring 160,000 shares of common stock on February 20, 2025.
Director Lawrence Steinman acquired 65,000 shares of 180 Life Sciences Corp. common stock on February 20, 2025, as compensation for services.
Director Ryan Lewis Smith acquired 65,000 shares of 180 Life Sciences Corp. common stock on February 20, 2025, as compensation for services rendered.
CEO Blair Jordan gains voting power over 43,166 shares of 180 Life Sciences Corp. common stock through a voting agreement with Dr. James Woody.